Fig 1.
Trop-2 mRNA expression distribution across multiple solid tumor types in TCGA.
Trop-2 expression in NSCLC LUAD and LUSC is highlighted in blue. Trop-2 mRNA expression is shown as log2 of the transcript count per million (log2TPM+1) and median expression is shown along x-axis for each indication. Abbreviations: ACC, adrenocortical carcinoma; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; DLBC, lymphoid neoplasm diffuse large B-cell lymphoma; ESCA, esophageal carcinoma; GBM, glioblastoma; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LGG, low grade glioma; LIHC, liver hepatocellular carcinoma; MESO, mesothelioma; OV, ovarian serous cystadenocarcinoma; PAAD, pancreatic adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; SARC, sarcoma; SKCM, skin cutaneous carcinoma; STAD, stomach adenocarcinoma; TACSTD2, tumor-associated calcium signal transducer 2; TGCT, tenosynovial giant cell tumor; THCA, thyroid carcinoma; THYM, thymoma; UCEC, uterine corpus endometrial carcinoma; UCS, uterine carcinosarcoma; UVM, uveal melanoma.
Fig 2.
Trop-2 mRNA expression in NSCLC in TCGA datasets.
Comparison of Trop-2 mRNA expression is shown in LUAD and LUSC histological subtypes (A), across stages I-IV for each subtype (B), mutation status of LUAD and LUSC combined of TP53 (C), KRAS (D), EGFR (E) and grouping of multiple oncogenes including EGFR, MET, ERBB2, BRAF, NTRK, PI3KCA, ALK, ROS, RET, but excluding KRAS (F). Abbreviations: ALK, anaplastic lymphoma kinase; BRAF, v-raf murine sarcoma viral oncogene homolog B1; EGFR, epidermal growth factor receptor; ERBB2, human epidermal growth factor receptor 2; KRAS, Kirsten rat sarcoma viral oncogene homolog; MET, mesenchymal epithelial transition factor; NTRK, neurotrophic tyrosine receptor kinase; PIK3CA, phosphatidylinositol 4,5 bisphosphate 3 kinase catalytic subunit alpha; RET, ret proto oncogene; ROS, c ros oncogene 1; TP53, tumor protein 53.
Fig 3.
Prognostic analysis of Trop-2 mRNA expression in NSCLC in TCGA.
Kaplan–Meier analysis of overall survival in LUAD (A) and LUSC (B) patients based on Trop-2 mRNA expression split into tertiles with upper, middle, and lower thirds indicated as light, medium, and dark colors, respectively, is shown. Patient numbers and events are summarized in 4-month increments. The table summarizes each Trop-2 tertile median OS and 95% CI and HR with 95% CI based on multivariate Cox proportional hazards model. Results were adjusted for age, MSI score, sex mutational load, and specific gene alterations including ALK, ROS1, RET, EGFR, and KRAS. Abbreviations: OS, overall survival; ref, reference.
Fig 4.
Trop-2 mRNA expression in an NSCLC adenocarcinoma sample set 1.
Trop-2 mRNA expression distribution in the sample set (A), comparison of expression across stages I through IV (B), between mutant and wildtype TP53 (C) and KRAS (D) is shown. NA indicates samples without stage information. Abbreviations: Mut, mutant; WT, wildtype.
Fig 5.
Trop-2 protein expression in an NSCLC adenocarcinoma sample set 1.
Trop-2 protein expression is shown as membrane H-score (A). The correlation between Trop-2 membrane H-score and the percentage of Trop-2-membrane positive tumor cells (at 4 × objective magnification) is shown in the scatter plot (r = 0.85, P < 0.001) (B). Correlation between Trop-2 mRNA and protein expression is shown in a scatter plot (C). Trop-2 protein expression across stages I through IV (D), in mutant and wildtype TP53 (E), and KRAS (F) is shown.
Fig 6.
Trop-2 mRNA and protein expression in an NSCLC adenocarcinoma and squamous cell carcinoma sample set 2.
Trop-2 mRNA and protein expression distribution across histological subtypes is shown (A, B). Trop-2 H score and % membrane positive tumor cells correlation depicted in scatter plot (C). Correlation between Trop-2 mRNA and protein expression is shown in a scatter plot (D). Trop-2 protein expression relative to TP53- and KRAS-mutated and WT specimens is shown (E). NSCLC Trop-2 protein immunohistochemistry in NSCLC adenocarcinoma and squamous cell carcinoma sample set 2. Representative images of Trop-2 protein expression in adenocarcinoma and squamous cell carcinoma is shown (F). Trop-2 expression in adenocarcinoma specimens at low (H-score 24), medium (H-score 155) and high (H-score 297) levels are illustrated (left images). Trop-2 expression in squamous cell carcinoma specimens at low (H-score 40), medium (H-score 160) and high (H-score 226) levels are shown (right images). Corresponding H&E images are shown below immunohistochemistry images. All images were captured at 20 × objective magnification. Abbreviations: H&E, hematoxylin and eosin; SCC, squamous cell carcinoma.